BEDFORD, Mass.–(BUSINESS WIRE)–lt;a href="" target="_blank"gt;$OCULlt;/agt; lt;a href="" target="_blank"gt;#OCUTXlt;/agt;–Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has entered into a note purchase agreement with an accredited investor to issue $37.5 million aggregate principal amount of 6.00% subordinated convertible notes due 2026 pursuant to Regulation D promulgated under the Securities Act of 1933, as a

Source link